报告题目：Role of miRNA and alternate splicing in regulating the expression and activity of the UDP-glucuronosyltransferases

报告人：Prof. Philip Lazarus，华盛顿州立大学

时间：2017年12月12日 星期二 上午9:30

地点：逸夫教学楼301

报告人简介：

Philip Lazarus was born and raised in Montreal Canada where he earned his BSc (Genetics) and PhD (Experimental Medicine) and performed postdoctoral studies at McGill University. After moving to the USA in 1990, he became Program Leader of the Cancer Epidemiology and Prevention Program at the H. Lee Moffitt Cancer Center (Tampa, FL) from 2001-2003, and was Associate Director of the Division of Population Sciences at the Penn State Cancer Institute (Hershey, PA) from 2003-2011. In 2012, he moved to Washington State University to serve as Chair of the Department of Pharmaceutical Sciences in the College of Pharmacy. His research has been focused on the metabolism of drugs and tobacco constituents, and how individual genetic variants play a role in cancer risk and drug toxicity and effectiveness. His laboratory was one of the first to study gene-environment interactions and their role in head and neck as well as lung cancer risk, and is considered one of the world experts on nicotine and tobacco-specific nitrosamine metabolism and the UGT family of metabolizing enzymes. In recent studies, he has examined the role genetics plays in susceptibility to tobacco-related aerodigestive tract cancer, and has used that insight to develop novel tobacco cessation agents. Dr. Lazarus has been continuously funded by the National Institutes of Health (NIH; USA) since 1995, and has received >$18.5 million from NIH to date. He has published over 170 peer-reviewed papers in high-impact journals, and serves on the editorial board ofMolecular Pharmacology. He has mentored over 30 graduate students and 23 postdoctoral fellows. He was a member of the NIH Cancer, Sleep, and Epidemiology study section (2013-2017), and has chaired and presented at numerous national and international meetings.

Current NIH grants are focused on how tobacco carcinogens are detoxified in target tissues such as lung and esophagus, and what enzymes play a role in that process. This will help researcher better develop markers that will help identify individuals that are more susceptible to tobacco carcinogens and allow for targeted prevention strategies. Another project is focused on the pharmacogenetics of breast cancer therapies, to determine how genetic variants affect the efficacy and toxicity of commonly used agents.

欢迎广大师生参与交流！